To assist the board to assess high value research projects, our Scientific Advisory Committee is comprised of prominent experts in medicine, research and higher education sectors.

Dr Russell Basser – Chair

Dr Russell Basser is a qualified physician and spent 10 years in an academic clinic Medical Oncology/Haematology. Since joining CSL (a leading biopharmaceutical company specialising in plasma-derived, recombinant protein therapeutics and influenza vaccines) in 2001, he has worked in a wide range of therapeutic areas and overseen clinical development, clinical operations, regulatory affairs, drug safety and biometrics/medical writing.

Alan Liddle

Alan Liddle has over 30 years' experience in developing and commercialising medical and biological therapeutics and over 30 years’ research & executive management experience in the medical and the biotechnology research sector, encompassing immunology and bio-therapeutics for cancer and auto-immune diseases, cardiology, neuroplasticity, the microbiome, regenerative medicine & rehabilitation. Alan is Executive Director of Sangui Bio, a company he cofounded in 2014.

Dr Gabby Goldberg

Dr Gabby Goldberg is Operations Manager of Synthesis Research and its investee companies Anaxis Pharma and Catalyst Therapeutics – joint ventures with the Walter and Eliza Hall Institute of Medical Research. She has over 15 years’ experience leading translational research. Her PhD with Prof Richard Boyd at Monash University resulted in several high-impact publications and a multi-centre clinical trial. She went on to do post-doctoral fellowships in translational immunology at Memorial Sloan-Kettering Cancer Center and Baylor Institute of Immunology Research.

Dr Michal Milgrom-Hoffman

Dr Michal Milgrom-Hoffman is currently a Research Fellow in the Department of Biochemistry, Latrobe University and a member of the Humbert Cancer biology, cell polarity and tissue architecture research team under Prof Patrick Humbert looking at how cell asymmetry and tissue organization can regulate cancer initiation, progression and metastasis with the ultimate aim to devise therapeutics to help tumours ‘reorganize’ themselves, thereby stopping the cancer’s growth and spread. The team works closely with cancer clinicians, pathologists, immunologists, a geneticist and a crystallographer.

Prof Jeffrey Zajac AO

Prof Jeffrey Zajac is Professor and Head of the University of Melbourne, Department of Medicine at Austin Health. He is a Clinical Endocrinologist and General Physician with research interests in molecular endocrinology. He is Chairman of Medicine and Director of the Department of Endocrinology at Austin Health. His research group has embarked on a major research program investigating the effect of androgen deprivation therapy in patients with prostate cancer.